ReviewKidney medicine2025
Hypomagnesemia With Metformin Use in Diabetes Mellitus: A Case and Narrative Review.
Review in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum magnesium and risk of arteriovenous fistula thrombosis in hemodialysis: a retrospective cohort study.BMC nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypomagnesemia is defined as a serum magnesium level <1.7 mg/dL, and it can be induced by gastrointestinal losses or renal wasting of magnesium. This is a common electrolyte abnormality in patients with diabetes mellitus. Refractory hypomagnesemia presents a significant challenge in clinical management, because some patients are prone to developing severe, recurrent hypomagnesemia that is refractory to aggressive repletion. In diabetes, insulin resistance in renal tissue inhibits magnesium reabsorption and contributes to the hypomagnesemia observed in these patients. Hypomagnesemia has also been reported with use of metformin and may be because of gastrointestinal wasting and intracellular accumulation. Chronic use of metformin suppresses transient receptor potential cation channel subfamily M member 6 in the kidneys, although it also appears to reduce urinary magnesium excretion. In addition to repletion aadnd using potassium-sparing diuretics, substituting sodium-glucose cotransporter 2 inhibitors for metformin may be helpful in managing refractory hypomagnesemia in patients with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.